We are a clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis, or CF, through theratyping, or the process of matching modulators to individual response to treatment regardless of CFTR mutations. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator, or CFTR protein. Although, CF is defined as a monogenic recessive genetic disorder caused by mutations in the CFTR gene, there is a broad range of disease activity for different organ systems in CF, including lung disease, meconium ileus, diabetes, and liver disease, even for CF patients who are homozygous for the most common mutation, F508del mutation. In summary, CF genotype does not always match CF phenotype.
Market Cap | 12.021 Million | Shares Outstanding | 10.83 Million | Avg 30-day Volume | 44.928 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.96 |
Price to Revenue | 3.9851 | Debt to Equity | 0.5602 | EBITDA | -38.198 Million |
Price to Book Value | 1.3643 | Operating Margin | -481.66339999999997 | Enterprise Value | 8.717 Million |
Current Ratio | 1.885 | EPS Growth | 0.822 | Quick Ratio | 1.831 |
1 Yr BETA | 1.9572 | 52-week High/Low | 16.89 / 0.95 | Profit Margin | -491.0865 |
Operating Cash Flow Growth | -172.6893 | Altman Z-Score | -5.2049 | Free Cash Flow to Firm | -40.214 Million |
Please sign in first
none
10.7 Thousand total shares from 1 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
PETERS RICHARD PRESIDENT AND CEO |
|
115,708 | 2022-03-28 | 3 |
MOHSEN PAULASH CHIEF BUSINESS OFFICER |
|
59,135 | 2022-02-03 | 2 |
SMITH DEVIN WHITTEMORE SVP AND GENERAL COUNSEL |
|
20,000 | 2021-12-01 | 3 |
VERMA AJAY EVP, HEAD OF R&D |
|
30,200 | 2021-12-01 | 2 |
EPSTEIN MARIE PRINCIPAL ACCOUNTING OFFICER |
|
12,665 | 2021-12-01 | 1 |
WYZGA MICHAEL D SEE REMARKS |
|
20,000 | 2021-12-01 | 3 |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
|
14,800 | 2021-06-02 | 1 | |
COLES N ANTHONY EXECUTIVE CHAIR |
|
78,650 | 2021-04-01 | 0 |
ROBERTSON BRIGITTE CHIEF MEDICAL OFFICER |
|
0 | 2021-02-01 | 0 |
SUSAN L. LINDQUIST FAMILY TRUST SUSAN L. LINDQUIST EXEMPT MARITAL TRUST |
|
1,184,561 | 2020-12-22 | 0 |
|
0 | 2020-06-29 | 0 | |
|
0 | 2020-06-29 | 0 | |
|
0 | 2020-06-29 | 0 | |
ALFIERI MICHAEL INTERIM HEAD OF FINANCE |
|
0 | 2020-05-12 | 0 |
CHHABRA MEENU PRESIDENT AND CEO |
|
0 | 2020-03-02 | 0 |
MUNOZ BENITO CHIEF SCIENTIFIC OFFICER |
|
0 | 2020-03-02 | 0 |
LARSON ERIC D SEE REMARKS |
|
0 | 2020-03-02 | 0 |
GILMARTIN GEOFFREY S. CHIEF MEDICAL OFFICER |
|
0 | 2020-03-02 | 0 |
ZECEVIC MARIJA CHIEF COMMERCIAL OFFICER |
|
0 | 2020-03-02 | 0 |
WILSON SHEILA CHIEF OPERATING OFFICER |
|
0 | 2020-03-02 | 0 |
NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP |
|
No longer subject to file | 2019-11-26 | 0 |
LEE PO SHUN SEE REMARKS |
|
0 | 2019-03-01 | 0 |
ZIMMERMAN SANDRA M. SEE REMARKS |
|
0 | 2018-08-06 | 0 |
|
0 | 2018-06-15 | 0 | |
|
0 | 2018-06-15 | 0 | |
BOUDREAU HELEN M CHIEF FINANCIAL OFFICER |
|
0 | 2018-03-01 | 0 |
CORMORANT ASSET MANAGEMENT, LLC |
|
No longer subject to file | 2017-12-14 | 0 |
HAGEN BRETT R SEE REMARKS |
|
0 | 2017-04-03 | 0 |
|
No longer subject to file | 2017-03-13 | 0 | |
NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP |
|
3,554,610 | 2016-09-14 | 0 |
DETORE JAMES M. SEE REMARKS |
|
0 | 2016-08-04 | 0 |
HEALTHCARE VENTURES VIII, L.P. |
|
2,164,095 | 2016-02-17 | 0 |
|
No longer subject to file | 2016-02-17 | 0 | |
|
2,908,067 | 2016-02-10 | 0 | |
|
0 | 2016-02-10 | 0 | |
THIBAULT LANCE E SEE REMARKS |
|
0 | 2016-02-10 | 0 |
|
0 | 2016-02-10 | 0 | |
|
0 | 2016-02-10 | 0 | |
MIRZAC ROMEO PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2016-02-10 | 0 |
SMART JANET L SEE REMARKS |
|
0 | 2016-02-10 | 0 |
|
0 | 2016-02-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-03-30 16:05:14 -0400 | 2022-03-28 | S | 10,715 | $1.85 | d | 115,708 | direct | yes | 2.0 | 6.0 | -20.0 | 6.0 | 6 | -32.0 | 30 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 19:15:03 UTC | -0.3826 | 1.2026 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 18:45:03 UTC | -0.3826 | 1.2026 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 18:15:03 UTC | -0.3826 | 1.2026 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 17:45:03 UTC | -0.3826 | 1.2026 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 17:15:03 UTC | -0.3826 | 1.2026 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 16:45:03 UTC | -0.443 | 1.263 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 16:15:03 UTC | -0.443 | 1.263 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 15:45:03 UTC | -0.443 | 1.263 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 15:15:03 UTC | -0.443 | 1.263 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 14:45:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 14:15:04 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 13:45:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 13:15:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-18 12:45:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 22:15:04 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 21:45:04 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 21:15:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 20:45:03 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 20:15:05 UTC | -0.4303 | 1.2503 | 150000 |
YUMANITY THERAPEUTICS INC YMTX | 2022-05-17 19:45:04 UTC | -0.4303 | 1.2503 | 150000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|